For example, does a BRCA mutated cell lose its synergism with PARPis in general, and with OLA in particular, if it is also mutated in CDKN2A? Could this be an explanation of why some BRCA-mutated breast cancers do not respond to OLA? This evidence concerns the gene CDKN2A and breast carcinoma.